Preliminary evidence suggests that the combination of magnesium and ibogaine, an atypical psychedelic, may be a promising treatment for post-traumatic stress disorder (PTSD), opioid use disorder, and traumatic brain injury (TBI). The "mystical" experience elicited by ibogaine, which is characterized by feelings of awe, selflessness, and transcendence, is correlated with improvements in PTSD...
Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...
BackgroundIbogaine was recently found to result in significant functional improvements in treating the sequelae of traumatic brain injury (TBI) among Special Operations Forces veterans (SOVs). In the current study, we used multimodal neuroimaging to elucidate the neural correlates of ibogaine in 30 male SOVs who received ibogaine treatment.MethodsArterial spin labeling and blood oxygen...
Abstract Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including posttraumatic stress disorder (PTSD), depression, and anxiety. Ibogaine, an oneirogenic alkaloid with unique pharmacological properties, has shown initial promise as a potential treatment for TBI-related sequelae. We previously observed large...
Traumatic brain injury (TBI) is a leading cause of disability. Sequelae can include functional impairments and psychiatric syndromes such as post-traumatic stress disorder (PTSD), depression and anxiety. Special Operations Forces (SOF) veterans (SOVs) may be at an elevated risk for these complications, leading some to seek underexplored treatment alternatives such as the oneirogen ibogaine, a...